The SERD improved survival endpoints compared to standard adjuvant endocrine therapy in a Phase III trial that may support ...

The AI-driven platform identifies cell cycle deregulation and tumor immune microenvironment dynamics from biopsy images.

Once the exchange agreements close, Sarepta will have $893.4 million in debt due in 2030 following previous refinancing it announced in August.

Although the readout was only from four multiple myeloma patients, attendees at the meeting wondered at how far the CAR T-cell therapy field has come.

Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...

The firm plans to seek accelerated approval from the FDA next year, while it launches a Phase III trial to support other regulatory applications.

Researchers have given the gene therapy made at UManchester to two out of five planned patients in a Phase I/II trial, and ...

A new analysis presented at ASH found Black AML patients were five years younger, on average, than White patients, and less ...

Researchers also discussed access barriers at the meeting, and a survey found distance was a major hindrance to CAR-T ...

Waskyra, developed by Fondazione Telethon, is the first gene therapy that the FDA has approved from a nonprofit applicant.

Patient drug sensitivity profiles were linked to their genomic mutation profiles and could provide prognostic and survival data.

At SABCS, Mayo Clinic researchers reported PRS data was more likely to change the risk categories of people with variants in moderate risk penetrance genes.